Safety of Combination Biologic and Antirejection Therapy Post–Liver Transplantation in Patients With Inflammatory Bowel Disease

Background Patients with inflammatory bowel disease (IBD) post–liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review. Methods Inflammatory bowel disease patients undergoing LT between 1985 and 2018 and requiring combination biologic and antirejection...